Skip to content

Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508069-34-01
Enrollment
70
Registered
2024-06-03
Start date
2024-08-05
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Brief summary

Identification of cell/molecular biomarkers correlated with individual patients’ responses. These could be: frequencies of cell (sub)populations, gene expression pattern, cell activation statues/phenotype, expression/production pattern of cell products, Identification of immunological mechanisms behind responses to mepolizumab, Evidence for the effectiveness in in vitro setting of mepolizumab in certain CRSsNP patients / endotypes

Detailed description

For CRSwNP group: Change in SNOT-22 from baseline to 6 months post-treatment

Interventions

Sponsors

Amsterdam UMC
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Identification of cell/molecular biomarkers correlated with individual patients’ responses. These could be: frequencies of cell (sub)populations, gene expression pattern, cell activation statues/phenotype, expression/production pattern of cell products, Identification of immunological mechanisms behind responses to mepolizumab, Evidence for the effectiveness in in vitro setting of mepolizumab in certain CRSsNP patients / endotypes

Secondary

MeasureTime frame
For CRSwNP group: Change in SNOT-22 from baseline to 6 months post-treatment

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026